UK biopharmaceutical companies saw a surge in venture financing for innovator drugs in 2024, with double the total deal value ...

Isomorphic Labs has raised a whopping $600 million to refine its artificial intelligence-powered drug discovery engine, advance its pipeline, and expand its headcount in its first external funding ...

While AI-generated drugs grab headlines, the technology is making more of an impact doing less “glamorous” tasks.

Isomorphic Labs launches into an already well-populated drug discovery category, with many large drugmakers exploring the technology along with a host of specialist players like Exscientia ...

We must turn our attention to how AI's greatest strengths are dramatically improving innovation for creating real societal ...

Rivalry from companies like Relay Therapeutics, Isomorphic Labs, and even tech giants like Alphabet and Microsoft could challenge RXRX’s ability to differentiate itself and sustain its ...

securing four out of the top 10 deals including the biggest in Europe after London-based AI drug discovery Isomorphic Labs scooped a £453m award.” For comparison, the nearest other countries in ...

Recursion Pharmaceuticals RXRX shares have plunged 21.6% so far in May. This considerable decline in the stock was observed ...

This symposium will showcase the state of the art in chemical biology, bringing together the wider community with leading national and international experts in the field. The event covers cutting edge ...

One of the improvements in AlphaFold 3, which DeepMind made together with its drug-discovery spin-off Isomorphic Labs, is more-accurate structure predictions for protein and nucleic acid complexes.

Artificial intelligence is gaining ground in healthcare, and tech's biggest players are racing to stake their claims.